Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Date: December 15, 2013
Pages: 106
Price:
US$ 3,500.00
License [?]:
Publisher: GBI Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M85EAE0ACDAEN
Leaflet:

Download PDF Leaflet

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Summary

GBI Research has released the pharma report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease.

Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer.

However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019.

Scope
  • A brief introduction to the two indications, including the disease’s pathogenesis, risk factors, diagnosis and treatment algorithms.
  • In-depth analysis of Herceptin, including analysis of its safety, efficacy, treatment patterns and strengths/weaknesses.
  • A comprehensive review of the pipeline for mAbs in gastric and esophageal cancer, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
  • Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth.
Reasons to buy
  • Understand the unmet need in the treatment of these cancers, the role of Herceptin and the areas of opportunity for other mAbs to enter the market.
  • Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
  • Observe the trends in clinical trial duration, size and molecule types across the phases of development and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for mAbs in gastric and esophageal cancers.
  • Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the market for mAbs in gastric and esophageal cancers.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Symptoms
  2.1.1 Early Gastric Cancer
  2.1.2 Early Esophageal Cancer
  2.1.3 Advanced Gastric or Esophageal Cancer
2.2 Etiology
  2.2.1 Esophageal Cancer
  2.2.2 Gastric Cancer
2.3 Epidemiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Prognosis and Disease Staging
2.7 Treatment Options
  2.7.1 Chemotherapy
  2.7.2 Targeted Therapies
  2.7.3 Treatment Guidelines
  2.7.4 Resistance to Pharmacological Therapies

3 MONOCLONAL ANTIBODIES MARKET IN GASTRIC AND ESOPHAGEAL CANCERS TO 2019- MARKETED PRODUCTS

3.1 Herceptin (Trastuzumab) - Hoffman La Roche

4 MONOCLONAL ANTIBODIES MARKET IN GASTRIC AND ESOPHAGEAL CANCERS TO 2019- DEVELOPMENTAL PIPELINE

4.1 Gastric Cancer
  4.1.1 Overall Pipeline
  4.1.2 Molecular Targets
  4.1.3 Clinical Trials
  4.1.4 Conclusion
4.2 Esophageal Cancer
  4.2.1 Overall Pipeline
  4.2.2 Molecular Targets
  4.2.3 Clinical Trials
  4.2.4 Conclusion
4.3 Key Late-Stage Pipeline Products
  4.3.1 AMG 102 (rilotumumab) - Amgen
  4.3.2 IMC-1121B (Ramucirumab) - Eli Lilly and Company
  4.3.3 Theraloc (Nimotuzumab) - YM Biosciences
  4.3.4 MetMAb (Onartuzumab) - F. Hoffmann-La Roche
  4.3.5 Perjeta (pertuzumab) - F. Hoffmann-La Roche
  4.3.6 Kadcyla (ado-trastuzumab emtansine) - F. Hoffmann-La Roche
4.4 Conclusion

5 MONOCLONAL ANTIBODIES MARKET IN GASTRIC AND ESOPHAGEAL CANCERS TO 2019- MARKET FORECAST TO 2019

5.1 Gastric Cancer
  5.1.1 Global
  5.1.2 US
  5.1.3 Canada
  5.1.4 Europe
  5.1.5 Japan
5.2 Esophageal Cancer
  5.2.1 Global
  5.2.2 US
  5.2.3 Canada
  5.2.4 Europe
  5.2.5 Japan
5.3 Drivers and Barriers
  5.3.1 Drivers
  5.3.2 Barriers

6 DEALS AND STRATEGIC CONSOLIDATIONS

6.1 Licensing Agreements
  6.1.1 Gastric Cancer
  6.1.2 Esophageal Cancer
6.2 Co-Development Agreements
  6.2.1 Gastric Cancer
  6.2.2 Esophageal Cancer

7 APPENDIX

7.1 Market Definitions
7.2 Abbreviations
7.3 References
7.4 All Pipeline Products, by Stage of Development
  7.4.1 Gastric Cancer
  7.4.2 Esophageal Cancer
7.5 Tabular Forecast Data
  7.5.1 Gastric Cancer
  7.5.2 Esophageal Cancer
7.6 Research Methodology
  7.6.1 Coverage
  7.6.2 Secondary Research
  7.6.3 Therapeutic Landscape
  7.6.4 Epidemiology-Based forecasting
  7.6.5 Market Size by Geography
  7.6.6 Geographical Landscape
  7.6.7 Pipeline Analysis
  7.6.8 Competitive Landscape
  7.6.9 Expert Panel Validation
7.7 Contact Us
7.8 Disclaimer

LIST OF FIGURES

Figure 1: Gastric Cancer: Treatment Algorithm
Figure 2: Esophageal Cancer: Treatment Algorithm (Locoregional Tumor)
Figure 3: Market for mAbs in Gastrointestinal Tract Cancer, Global, Sales of Herceptin ($bn), 1999-2012
Figure 4: Market for mAbs in Gastric Cancer, Global, Overall Pipeline, 2013
Figure 5: Market for mAbs in Gastric Cancer, Global, Pipeline mAbs by Mechanism of Action and Molecular Target, 2013
Figure 6: Market for mAbs in Gastric Cancer, Global, Developmental Pipeline Failure Rate, 2006-2013
Figure 7: Market for mAbs in Gastric Cancer, Global, Clinical Trial Sizes, 2006-2013
Figure 8: Market for mAbs in Gastric Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013
Figure 9: Market for mAbs in Gastric Cancer, Global, Clinical Trial Durations, 2006-2013
Figure 10: Market for mAbs in Gastric Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013
Figure 11: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints (All Molecule Types), 2006-2013
Figure 12: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints (mAbs Only), 2006-2013
Figure 13: Market for mAbs in Gastric Cancer, Global, Clinical Trial Primary Endpoints by Developmental Program (mAbs Only), 2006-2013
Figure 14: Market for mAbs in Esophageal Cancer, Global, Overall Pipeline, 2013
Figure 15: Market for mAbs in Esophageal Cancer, Global, Pipeline mAbs by Mechanism of Action, 2013
Figure 16: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Sizes, 2006-2013
Figure 17: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Sizes by Molecule Type, 2006-2013
Figure 18: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Durations, 2006-2013
Figure 19: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Durations by Molecule Type, 2006-2013
Figure 20: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints (All Molecule Types), 2006-2012
Figure 21: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints (mAbs Only), 2006-2012
Figure 22: Market for mAbs in Esophageal Cancer, Global, Clinical Trial Primary Endpoints by Developmental Program (mAbs Only), 2006-2012
Figure 23: Market for mAbs in Gastric Cancer, Global, Market Size and Growth, 2012-2019
Figure 24: Market for mAbs in Esophageal Cancer, Global, Market Size and Growth, 2012-2019
Figure 25: Market for mAbs in Gastric Cancer, Global, Treatment Usage Patterns, 2012-2019
Figure 26: Market for mAbs in Gastric Cancer, Global, Market Size ($m), 2012-2019
Figure 27: Market for mAbs in Gastric Cancer, US, Treatment Patterns, 2012-2019
Figure 28: Market for mAbs in Gastric Cancer, US, Market Size ($m), 2012-2019
Figure 29: Market for mAbs in Gastric Cancer, Canada, Treatment Usage Patterns, 2012-2019
Figure 30: Market for mAbs in Gastric Cancer, Canada, Market Size ($m), 2012-2019
Figure 31: Market for mAbs in Gastric Cancer, Top Five European Markets, Treatment Usage Patterns, 2012-2019
Figure 32: Market for mAbs in Gastric Cancer, Top Five European Markets, Annual Cost of Therapy, 2012-2019
Figure 33: Market for mAbs in Gastric Cancer, Top Five European Markets, Market Size ($m), 2012-2019
Figure 34: Market for mAbs in Gastric Cancer, Japan, Treatment Usage Patterns, 2012-2019
Figure 35: Market for mAbs in Gastric Cancer, Japan, Market Size ($m), 2012-2019
Figure 36: Market for mAbs in Esophageal Cancer, Global, Treatment Usage Patterns, 2012-2019
Figure 37: Market for mAbs in Esophageal Cancer, Global, Market Size ($m), 2012-2019
Figure 38: Market for mAbs in Esophageal Cancer, US, Treatment Patterns, 2012-2019
Figure 39: Market for mAbs in Esophageal Cancer, US, Market Size ($m), 2012-2019
Figure 40: Market for mAbs in Esophageal Cancer, Canada, Treatment Patterns, 2012-2019
Figure 41: Market for mAbs in Esophageal Cancer, Canada, Market Size ($m), 2012-2019
Figure 42: Market for mAbs in Esophageal Cancer, Top Five European Markets, Treatment Usage Patterns, 2012-2019
Figure 43: Market for mAbs in Esophageal Cancer, Top Five European Markets, Annual Cost of Therapy ($), 2012-2019
Figure 44: Market for mAbs in Esophageal Cancer, Top Five European Markets, Market Size ($m), 2012-2019
Figure 45: Market for mAbs in Esophageal Cancer, Japan, Treatment Patterns, 2012-2019
Figure 46: Market for mAbs in Esophageal Cancer, Japan, Market Size ($m), 2012-2019
Figure 47: Market for mAbs in Gastric Cancer, Global, Licensing Deals (Countries), 2006-2013
Figure 48: Market for mAbs in Gastric Cancer, Global, Licensing Deals by Year and Value, 2006-2013
Figure 49: Market for mAbs in Gastrointestinal Tract Cancers, Global, Licensing Deals, 2006-2013
Figure 50: Market for mAbs in Gastric Cancer, Global, Co-Development Deals, 2006-2013
Figure 51: GBI Research Market Forecasting Model

The market value for monoclonal antibodies (mAbs) in gastric and esophageal cancer treatment is expected to double by 2019, due to favorable market conditions in terms of US pricing structures and the anticipated approval of a number of late-stage pipeline drugs. The market for mAbs in gastric cancer will grow from $256m in 2012 to $501m by 2019, at a Compound Annual Growth Rate (CAGR) of 10%, while the mAbs market for esophageal cancer is expected to climb from $137m in 2012 to $265m by 2019, at a CAGR of 9.9%.

Currently, there is only one mAb - Herceptin - available for the two indications. Primarily marketed for breast cancer, Herceptin gained approval from the US Food and Drug Administration for the treatment of gastric and esophageal cancers in 2010. However, its patent is expected to expire in the European Union in 2014 and in the US by 2019.

Dominic Trewartha, Analyst for GBI Research, says: “Herceptin is able to improve survival times to a significant extent when compared with chemotherapy alone, without adding a substantial amount of side effects or safety concerns in Human Epidermal growth factor Receptor-2 (HER-2) positive patients. There is still a need for stronger products with superior efficacy to treat both gastric and esophageal cancers in the metastatic and early settings periods. Also, with a large HER-2 negative patient population that is not eligible for treatment with Herceptin, there is a strong unmet need and opportunity for therapies that are effective in these patients, including those who overexpress HER-2.”

"Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth" provides a comprehensive review of the pipeline for monoclonal antibodies (mAbs) in gastric and esophageal cancers, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market by 2019. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets. This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

The material was prepared in February, 2014.

LIST OF TABLES

Table 1: Market for mAbs in Gastrointestinal Tract Cancer, US, Epidemiology, 2008
Table 2: Market for mAbs in Gastrointestinal Tract Cancer, US, Diagnosis by Stage, 2008
Table 3: Market for mAbs in Gastrointestinal Tract Cancer, US, Five-Year Relative Survival by Stage, 2003-2009
Table 4: Market for mAbs in Gastric Cancer, Global, TNM Staging, 2010-2013
Table 5: Gastric Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 6: Gastric Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013
Table 7: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013
Table 8: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 9: Gastric Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-registration), 2013
Table 10: Gastric Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013
Table 11: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 12: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013
Table 13: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013
Table 14: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 15: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-registration), 2013
Table 16: Esophageal Cancer Therapeutics, Global, All Pipeline Products (Undisclosed), 2013
Table 17: Market for mAbs in Gastric Cancer, Global, Forecast Data, 2012-2019
Table 18: Market for mAbs in Gastric Cancer, US, Forecast Data, 2012-2019
Table 19: Market for mAbs in Gastric Cancer, Canada, Forecast Data, 2012-2019
Table 20: Market for mAbs in Gastric Cancer, UK, Forecast Data, 2012-2019
Table 21: Market for mAbs in Gastric Cancer, France, Forecast Data, 2012-2019
Table 22: Market for mAbs in Gastric Cancer, Germany, Forecast Data, 2012-2019
Table 23: Market for mAbs in Gastric Cancer, Italy, Forecast Data, 2012-2019
Table 24: Market for mAbs in Gastric Cancer, Spain, Forecast Data, 2012-2019
Table 25: Market for mAbs in Gastric Cancer, Japan, Forecast Data, 2012-2019
Table 26: Market for mAbs in Esophageal Cancer, Global, Forecast Data, 2012-2019
Table 27: Market for mAbs in Esophageal Cancer, US, Forecast Data, 2012-2019
Table 28: Market for mAbs in Esophageal Cancer, Canada, Forecast Data, 2012-2019
Table 29: Market for mAbs in Esophageal Cancer, UK, Forecast Data, 2012-2019
Table 30: Market for mAbs in Esophageal Cancer, France, Forecast Data, 2012-2019
Table 31: Market for mAbs in Esophageal Cancer, Germany, Forecast Data, 2012-2019
Table 32: Market for mAbs in Esophageal Cancer, Italy, Forecast Data, 2012-2019
Table 33: Market for mAbs in Esophageal Cancer, Spain, Forecast Data, 2012-2019
Table 34: Market for mAbs in Esophageal Cancer, Japan, Forecast Data, 2012-2019

Ask Your Question

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: